DiscoverRheumatology & Arthritis Learning NetworkRoy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA
Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Update: 2023-11-07
Share

Description

Dr Fleischmann reviews a post hoc analysis of the SELECT phase 3 trial of upadacitinib in rheumatoid arthritis and the safety of JAK inhibitors among RA patients at risk for cardiovascular events.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Rheumatology & Arthritis Learning Network